Asset profile
Equecabtagene autoleucel
Cell therapy
Evidence outlook
Approved: Relapsed/refractory multiple myeloma after >=3 prior lines (FUCASO) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 32 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 23 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Equecabtagene Autoleucel: this drug | Phase 3 | Cell therapy | BCMA | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Anitocabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | ||
| HRC0202 | Phase 2 | Cell therapy | BCMA | ||
| PHE885 | Phase 2 | Cell therapy | BCMA | ||
| AZD4045 | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Hrain) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Shenzhen Pregene Biopharma) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-CART (Bioray Laboratories) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech) | Phase 1/2 | Cell therapy | BCMA | ||
| GSK2857914 | Phase 1/2 | Monoclonal antibody | BCMA | ||
| Pamlectabart Tismanitin | Phase 1/2 | Adc (anti-bcma Antibody-targeted Amanitin Conjugate) | BCMA | ||
| SENL103 | Phase 1/2 | Cell therapy | BCMA | ||
| Trovocabtagene Autoleucel (C-CAR088) | Phase 1/2 | Cell therapy | BCMA |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
8 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.